Tofacitinib

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

Therapies for Down Syndrome Regression Disorder

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project

A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome